About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Pharma Roundup: Schering-Plough's $500,000 Bonus, Bristol and Exelixis, and More

By John Maas | Dec 12, 2008

Schering-Plough pays counsel $500,000 bonus as thousands lose jobs — A recent SEC filing revealed that Tom Sabatino, the company’s general counsel, received a $500,000 bonus for “strong performance” and “increased responsibility,” at a time when 5,500 S-P employees are losing their jobs in cost-cutting measures. [Source: Pharmalot]

Bristol-Myers Squibb borrows from Exelixis pipeline –For $195 million, BMS acquired development and commercialization rights to two late-stage cancer drugs from Exelixis. The Wall Street Journal called it one of the largest ever upfront payments to a biotech. [Source: FierceBiotech]

1,000 jobs lost between Pfizer and Elan — Both companies announced layoffs: an official 700 at Pfizer’s European headquarters in Paris (though the union claims 892), and 114 at Elan’s operations in New York and Tokyo. [Source: FiercePharma]

BNET User Analysis

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here